Literature DB >> 26107057

TREM2 and Risk of Alzheimer's Disease--Friend or Foe?

Rudolph E Tanzi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26107057     DOI: 10.1056/NEJMcibr1503954

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  24 in total

Review 1.  TREM2 variants: new keys to decipher Alzheimer disease pathogenesis.

Authors:  Marco Colonna; Yaming Wang
Journal:  Nat Rev Neurosci       Date:  2016-02-25       Impact factor: 34.870

2.  Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease.

Authors:  Taylor R Jay; Anna M Hirsch; Margaret L Broihier; Crystal M Miller; Lee E Neilson; Richard M Ransohoff; Bruce T Lamb; Gary E Landreth
Journal:  J Neurosci       Date:  2017-01-18       Impact factor: 6.167

3.  Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.

Authors:  Michael Ewers; Nicolai Franzmeier; Marc Suárez-Calvet; Estrella Morenas-Rodriguez; Miguel Angel Araque Caballero; Gernot Kleinberger; Laura Piccio; Carlos Cruchaga; Yuetiva Deming; Martin Dichgans; John Q Trojanowski; Leslie M Shaw; Michael W Weiner; Christian Haass
Journal:  Sci Transl Med       Date:  2019-08-28       Impact factor: 17.956

4.  Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model.

Authors:  Chad A Tagge; Andrew M Fisher; Olga V Minaeva; Amanda Gaudreau-Balderrama; Juliet A Moncaster; Xiao-Lei Zhang; Mark W Wojnarowicz; Noel Casey; Haiyan Lu; Olga N Kokiko-Cochran; Sudad Saman; Maria Ericsson; Kristen D Onos; Ronel Veksler; Vladimir V Senatorov; Asami Kondo; Xiao Z Zhou; Omid Miry; Linnea R Vose; Katisha R Gopaul; Chirag Upreti; Christopher J Nowinski; Robert C Cantu; Victor E Alvarez; Audrey M Hildebrandt; Erich S Franz; Janusz Konrad; James A Hamilton; Ning Hua; Yorghos Tripodis; Andrew T Anderson; Gareth R Howell; Daniela Kaufer; Garth F Hall; Kun P Lu; Richard M Ransohoff; Robin O Cleveland; Neil W Kowall; Thor D Stein; Bruce T Lamb; Bertrand R Huber; William C Moss; Alon Friedman; Patric K Stanton; Ann C McKee; Lee E Goldstein
Journal:  Brain       Date:  2018-02-01       Impact factor: 13.501

Review 5.  Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?

Authors:  Antoine Louveau; Sandro Da Mesquita; Jonathan Kipnis
Journal:  Neuron       Date:  2016-09-07       Impact factor: 17.173

Review 6.  The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases.

Authors:  Jochen Walter
Journal:  J Biol Chem       Date:  2015-12-22       Impact factor: 5.157

Review 7.  In vivo PET imaging of neuroinflammation in Alzheimer's disease.

Authors:  Julien Lagarde; Marie Sarazin; Michel Bottlaender
Journal:  J Neural Transm (Vienna)       Date:  2017-05-17       Impact factor: 3.575

Review 8.  Is amyloid-β harmful to the brain? Insights from human imaging studies.

Authors:  William Jagust
Journal:  Brain       Date:  2015-11-27       Impact factor: 13.501

Review 9.  Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.

Authors:  Todd E Golde
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

10.  Gene therapy for Alzheimer's disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation.

Authors:  Ana Griciuc; Anthony N Federico; Jeyashree Natasan; Angela M Forte; Danielle McGinty; Huong Nguyen; Adrienn Volak; Stanley LeRoy; Sheetal Gandhi; Eli P Lerner; Eloise Hudry; Rudolph E Tanzi; Casey A Maguire
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.